Suven Life SciencesQ2 FY19

Suven Life Sciences Q2 FY19 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268.65Market Cap: ₹7.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The core CRAMS business is in a growth phase and expected to grow around 10%-15% yearly.
  • Growth depends heavily on the success and progression of clinical trials for molecules in development.
  • There is an emphasis on transitioning molecules from Phase-1 to Phase-2 and later to Phase-3, with more activity expected from Phase-2 to Phase-3 over time.
  • The number of molecules in development has been reduced, focusing on fewer but more promising candidates, leading to better traction and continuation through clinical phases.
  • The company expects stability within next two to four quarters by securing raw material supplies despite current shortages.
  • Specialty CRAMS business is expected to remain flat, growing around 5%.
  • Commercial product revenues are anticipated to be around Rs. 60-90 crore yearly.
  • Out-licensing opportunities depend on positive clinical trial data, potentially driving significant growth.

See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript pages.
  • The focus appears to be on securing raw material supply, progressing clinical trials, and CAPEX spending rather than raising funds.
  • The company has planned CAPEX of Rs. 270 crore over 18 months, funded likely from internal resources or existing mechanisms; no mention of raising funds externally.
  • Research and development expenses and clinical trial costs are being managed within existing budgets without indications of new fundraising.
  • Out-licensing of the molecule SUVN-502 is considered a potential future monetization path, but no fundraising is planned related to this as of now.

See what Suven Life Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Planned CAPEX of Rs. 270 crore, with Rs. 70 crore already spent.
  • Additional Rs. 200 crore to be spent within the next 18 months (covering FY2019 and FY2020).
  • A significant portion (Rs. 120 crore) is allocated for constructing a new block with occupational exposure levels required for new CRAMS projects.
  • This CAPEX aims to meet future customer requirements and secure capacity for new and existing projects.
  • The new block investment can potentially be recovered within 18 months if orders are secured quickly, although it could take 2-3 years.
  • Efforts toward backward integration of raw materials are ongoing but are limited in scale due to cost-effectiveness.
  • Capacity utilization is currently at 100%.

Track Suven Life Sciences — get its next earnings analysis in your feed

How does Suven Life Sciences rank vs peers in Healthcare Services?

Pro feature
ThisSuven Life Sciences
Rev 3Mar 4

How does Suven Life Sciences rank in Healthcare Services?

Compare Suven Life Sciences against every Healthcare Services company (Q2 FY19) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →